Study Condition(s): Stomach Cancer, Gastroesophageal Junction Cancer (GEJ)
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
Study Alias: JVCZ
The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma (GEJ).
The results of this study are not yet available.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have a diagnosis of Gastric Cancer (gastric or gastroesophageal junction adenocarcinoma (GEJ) adenocarcinoma)
Participant must have disease progression during or within 4 months after last dose of first-line chemotherapy
Participant must have received combination chemotherapy
Male participants must be sterile or agree to use a reliable method of birth control
Female participants of child-bearing potential must have a negative pregnancy test and agree to use a highly effective method of birth control; all other female participants must be surgically sterile or postmenopausal
Participant must not have known brain metastases or leptomeningeal disease
Participant must not have a history of gastrointestinal perforation or fistula within 6 months
Participant must not have a history of inflammatory bowel disease or Crohn's disease requiring medical intervention within 12 months
Participant must not have Child-pugh B, C cirrhosis or HIV